The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety,tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium(177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 andhereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) inparticipants with metastatic castration resistant prostate cancer (mCRPC) who have failedone prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluatethe preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participantswith mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxanetreatment.
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety,tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium(177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 andhereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) inparticipants with metastatic castration resistant prostate cancer (mCRPC) who have failedone prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluatethe preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participantswith mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxanetreatment.
